PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “IODINE, RADIOACTIVE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1994

Chromosome aberrations after treatment with radioactive iodine for thyroid cancer.

The study aimed to investigate whether the determination of chromosome aberrations in circulating blood lymphocytes could be useful to assess whole-body exposure from radioactive iodine released accidentally. Ten patients treated with two doses of 1850 MBq of 131I given 24 h apart for thyroid cancer were studied for chromosome aberrations (dicentrics) in blood samples taken before and at various times after exposure. The increase in the yield of aberrations caused by the exposure to iodine was small but statistically significant. Compared to published values for whole-body doses after such treatment, this increase appears to be somewhat smaller than expected from dose-effect relationships obtained for an acute exposure of lymphocytes in vitro or in vivo, a fact which could be explained by the low dose rate of the 131I exposure. Thus, in situations where a population was exposed as a result of the release of radioactive iodine, a determination of chromosome aberrations in blood lymphocytes would not appear to be very useful to determine exposure from iodine.

Chromosome Aberrations↗
PubMedDate not supplied

[Thyroiditis induced by radioactive iodine (I-131). Report of a case and review of the literature].

A 23 years old female with Graves' disease initiated a symptomatic treatment with propanolol and then received radioactive iodine (I-311) 370 MBq (10 mCi) as definitive treatment. Three weeks later she was hospitalized because she presented acute radiation thyroiditis. She was discharged after 48 h of treatment, but clinical symptoms and signs persisted for over 30 days, but in less degree. One month later she developed hypothyroidism. There are three therapeutics options for the treatment of Grave's disease (antithyroid drugs, radioiodine and surgery). There are some hospitals in which the use of radioactive iodine is preferred as the first option, without a pretreatment with antithyroid drugs, but this could lead to acute thyroiditis or thyroid storm.

Adult↗
PubMed2000

Use of thyroid ultrasound volume in calculating radioactive iodine dose in hyperthyroidism.

One hundred twenty-one patients treated with 131I had a thyroid ultrasound to measure thyroid volume precisely. This volume measurement was used to determine the radioactive iodine dose. The average size (+/-SEM) of the thyroid glands measured in this manner was 39.7 cm3 +/- 1.9 cc. A significant correlation was found in the estimated size of the gland by the endocrinologists and the ultrasound volume. Of the 121 patients, 89 patients had the same 131I microcurie per gram of tissue factor to determine the radioactive iodine dose. This group of patients was further evaluated in this study. The average 131I dose (+/-SEM) given was 13.2 mCi +/- 0.5 mCi. The average time until hypothyroidism was achieved 2.85 +/- 0.14 months. Ultrasound provides a safe and precise way to determine actual thyroid size when calculating 131I doses.

Dose-Response Relationship, Radiation↗
PubMed1999

[Radioactive iodine (I-131) therapy].

It was in 1942 that radioactive iodine, I-131, was applied to therapy of Graves' disease. Recently, this therapy is popular in Japan because the maximum therapeutic dose of I-131 for outpatients was estimated. The feature of I-131 therapy in patients with hyperthyroidism due to Graves' disease is as follow as; 1. The most effective method of I-131 therapy is performed under the state of hyperthyroidism. 2. The symptom of hyperthyroidism will be disappeared from 1 month after the therapy gradually. 3. Transient hypothyroidism may be appeared 3-4 months after the therapy. 4. Hypothyroidism after I-131 therapy will be difficult to avoid in their future. I-131 therapy should be undertaken in the patients with uncontrolled hyperthyroidism by medication of anti-thyroid drug.

Graves Disease↗
PubMed2005

[Changes in thyroid volume after radioactive iodine therapy in patients with single toxic thyroid nodule].

Radioactive iodine (131I) is a well-established therapeutic modality in the treatment of toxic solitary autonomous thyroid nodules. This method is preferred in patients with small, benign nodules. The aim of our study was to investigate the effects of radioiodine therapy on thyroid size in patients with a solitary toxic thyroid nodule. 22 patients with single nodule in USG and confirmed "hot" nodule in scintigraphy were enrolled in the study. Thyroid and nodule volume were determined by ultrasound before, 3 and 6 months after the administration of 131I. Thyroid function was assessed by TSH level prior to the treatment and 6 weeks after the therapy. Thyroid volume and nodule size decreased significantly within 3 and 6 months after 131I treatment. The mean reduction of thyroid volume within 6 month after treatment was 32%. Reduction in thyroid volume and nodule, size was significantly greater within first 3 months than within next 3 months. Patients with smaller nodules (less than 70% of thyroid volume) were characterized by greater reduction of goiter size than patients with nodules bigger or equal to 70% of thyroid volume.

Dose-Response Relationship, Radiation↗
PubMed2006

Patient misconceptions and ethical challenges in radioactive iodine scanning and therapy.

The use and nature of radioactive iodine (RAI) are complex topics for patients with thyroid conditions to understand. Fear and anxiety over its use, misinformation in patient advocacy books and on the Internet, medical jargon, confusion regarding postscanning and posttreatment procedures, patient literacy, thyroid health status, and several other socioeconomic factors can create serious barriers to genuine informed consent in RAI scanning and treatment. The following discussion will review the origins of patient misconceptions and misinterpretations, including international differences in physician attitudes regarding RAI usage. Next, this article will present the core ethical duties, problems, and moral dilemmas that can arise in the RAI setting. Upon completion of this article, the reader should be able to describe the core ethical principles of respect for persons (patient autonomy), beneficence, nonmaleficence, and justice; describe the 3 components of informed consent; identify common barriers to informed consent and describe how such barriers can lead to misconceptions, misinformation, and refusal of treatment with RAI; and summarize where RAI candidates and patients first look for information and identify the common ways in which misinformation surfaces.

Attitude to Health↗
PubMed1981

[Monitoring of post-operative prevention of thrombosis by low dosage heparin with the radioactive iodine fibrinogen test (author's transl)].

In a prospective study low dosage subcutaneous heparin was administered to 148 patients after major gynaecological operations. The preventive effect on deep vein thrombosis was monitored by the radioactive iodine fibrinogen test. In 10.1% (15) of the cases higher than normal activity of the radioiodine fibrinogen test was detected. Only 4 patients (2.7%) had clinical signs of deep vein thrombosis. Because of the early occurrence of silent signs of deep vein thrombosis in the radioactive iodine fibrinogen test the onset of the subcutaneous heparin prophylaxis of thrombosis was shifted from the post-operative period to the pre-operative administration.

Adult↗
PubMed2003

The needs of family members of patients receiving radioactive iodine.

The current literature on radionuclide therapy is heavily based on health care professionals' perspectives and provides little insight regarding what patients or family members identify as their needs or concerns. Family members (N = 130) of patients undergoing treatment with radioactive iodine were selected from eight programs across Canada to participate in a survey to identify the needs they had when a close relative was undergoing treatment with radioactive iodine. The results of the survey indicated family members experienced worries and concerns about the patient being at home after treatment, and there was variation in their knowledge about what precautions were needed. Family members provided evidence that many experienced psychosocial distress, but very few received adequate assistance for their difficulties.

Adult↗
PubMed1992

Contrast material iodides: potential effects on radioactive iodine thyroid uptake.

The levels of contaminant, free inorganic iodide and iodine were determined in several commonly used ionic and nonionic intravenous contrast media to gain a better understanding of the roles of these compounds in radioactive iodine uptake inhibition. The method, which involved a reduction-oxidation reaction using sodium nitrite, yielded accurate and precise data for the iothalomate based ionic contrast media as well as the nonionic contrast media. There was no free iodine in any of the contrast media tested. There was considerable variation in free iodide levels, ranging from 1.38 microgram/ml to 20.84 microgram/ml among the different contrast media, although significant differences between the ionic and nonionic media were not found. These levels of contaminant iodide are thought to play a role in the short-term inhibition of radioactive iodine uptake.

Contrast Media↗